Gastroenterology
Volume 132, Issue 5 , Pages 1925-1936 , May 2007

Inhibition of T-Cell Inflammatory Cytokines, Hepatocyte NF-κB Signaling, and HCV Infection by Standardized Silymarin

  • Stephen J. Polyak

      Affiliations

    • Department of Laboratory Medicine, University of Washington, Seattle, Washington
    • Department of Microbiology, University of Washington, Seattle, Washington
    • Department of Pathobiology, University of Washington, Seattle, Washington
    • S. J. P. is partially supported by NIH Grants R01 DK 62187 and U19 AI 66328 from NIDDK and NIAID, respectively.
    • Corresponding Author InformationAddress requests for reprints to: S. J. Polyak, PhD, University of Washington, Virology 359690, 325 9th Avenue, Seattle, Washington 98104-2499. fax: (206) 341-5203.
    • ,
  • Chihiro Morishima

      Affiliations

    • Department of Laboratory Medicine, University of Washington, Seattle, Washington
    • ,
  • Margaret C. Shuhart

      Affiliations

    • Department of Medicine, University of Washington, Seattle, Washington
    • ,
  • Chia C. Wang

      Affiliations

    • Department of Medicine, University of Washington, Seattle, Washington
    • ,
  • Yanze Liu

      Affiliations

    • Department of Psychiatry, McLean General Hospital, Harvard Medical School, Boston, Massachusetts
    • Natural Pharmacia International Inc., Burlington, Massachusetts
    • ,
  • David Y.–W. Lee

      Affiliations

    • Department of Psychiatry, McLean General Hospital, Harvard Medical School, Boston, Massachusetts
    • D. Y. W.–L. is supported in part by NIH-STTR grant (R42-AT-00766) to Natural Pharmacia International Inc.

Received 7 November 2006 ,Accepted 8 February 2007.

References 

  1. Di Bisceglie AM. Liver transplantation for hepatitis C: the promise and the challenge. Hepatology. 1995;22:660–662
  2. Ferrell LD, Wright TL, Roberts J, Ascher N, Lake J. Hepatitis C viral infection in liver transplant recipients. Hepatology. 1992;16:865–876
  3. Davis GL, Albright JE, Cook SF, Rosenberg DM. Projecting future complications of chronic hepatitis C in the United States. Liver Transplant. 2003;9:331–338
  4. Fried MW, Shiffman M, Sterling RK, Weinstein J, Crippin J, Garcia G, et al. A multicenter, randomized trial of daily high-dose interferon-alfa 2b for the treatment of chronic hepatitis C: pretreatment stratification by viral burden and genotype. Am J Gastroenterol. 2000;95:3225–3229
  5. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975–982
  6. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358:958–965
  7. Rainone F. Milk thistle. Am Fam Physician. 2005;72:1285–1288
  8. Levy C, Seeff LD, Lindor KD. Use of herbal supplements for chronic liver disease. Clin Gastroenterol Hepatol. 2004;2:947–956
  9. Mayer KE, Myers RP, Lee SS. Silymarin treatment of viral hepatitis: a systematic review. J Viral Hepat. 2005;12:559–567
  10. Dhiman RK, Chawla YK. Herbal medicines for liver diseases. Dig Dis Sci. 2005;50:1807–1812
  11. Singh RP, Agarwal R. Mechanisms and preclinical efficacy of silibinin in preventing skin cancer. Eur J Cancer. 2005;41:1969–1979
  12. Singh RP, Agarwal R. Prostate cancer chemoprevention by silibinin: Bench to bedside. Mol Carcinog. 2006;45:436–442
  13. Singh RP, Dhanalakshmi S, Agarwal C, Agarwal R. Silibinin strongly inhibits growth and survival of human endothelial cells via cell cycle arrest and downregulation of survivin, Akt and NF-kappaB: implications for angioprevention and antiangiogenic therapy. Oncogene. 2005;24:1188–1202
  14. Singh RP, Mallikarjuna GU, Sharma G, Dhanalakshmi S, Tyagi AK, Chan DC, et al. Oral silibinin inhibits lung tumor growth in athymic nude mice and forms a novel chemocombination with doxorubicin targeting nuclear factor kappaB-mediated inducible chemoresistance. Clin Cancer Res. 2004;10:8641–8647
  15. NCCAM. Hepatitis C and Complementary and Alternative Medicine: 2003 Update. Research report: National Center for Complementary and Alternative Medicine, Bethesda, MD: 2003:2–20.
  16. Fong HH. Integration of herbal medicine into modern medical practices: issues and prospects. Integr Cancer Ther. 2002;1:287–293discussion 293
  17. Tyler VE. Herbal medicine: from the past to the future. Public Health Nutr. 2000;3:447–452
  18. Awang DV. Maternal use of ginseng and neonatal androgenization. JAMA. 1991;266:363
  19. Ernst E. Heavy metals in traditional Indian remedies. Eur J Clin Pharmacol. 2002;57:891–896
  20. Ernst E. Toxic heavy metals and undeclared drugs in Asian herbal medicines. Trends Pharmacol Sci. 2002;23:136–139
  21. Rai V, Agnihotri AK, Khatoon S, Rawat AK, Mehrotra S. Chromium in some herbal drugs. Bull Environ Contam Toxicol. 2005;74:464–469
  22. Lee DY, Liu Y. Molecular structure and stereochemistry of silybin A, silybin B, isosilybin A, and isosilybin B, isolated from Silybum marianum (milk thistle). J Nat Prod. 2003;66:1171–1174
  23. Liu YZ, Lee DYW. Standardization of Silymarin (MK-001), a popular seed extract of Silybum marianum (milk thistle) for liver protection. J Agric Food Chem. 2006;submitted
  24. Lindenbach BD, Rice CM. Unravelling hepatitis C virus replication from genome to function. Nature. 2005;436:933–938
  25. Lohmann V, Korner F, Koch J, Herian U, Theilmann L, Bartenschlager R. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science. 1999;285:110–113
  26. Blight KJ, Kolykhalov AA, Rice CM. Efficient initiation of HCV RNA replication in cell culture. Science. 2000;290:1972–1974
  27. Wakita T, Pietschmann T, Kato T, Date T, Miyamoto M, Zhao Z, et al. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med. 2005;11:791–796
  28. Kato T, Date T, Miyamoto M, Furusaka A, Tokushige K, Mizokami M, et al. Efficient replication of the genotype 2a hepatitis C virus subgenomic replicon. Gastroenterology. 2003;125:1808–1817
  29. Lindenbach BD, Evans MJ, Syder AJ, Wolk B, Tellinghuisen TL, Liu CC, et al. Complete replication of hepatitis C virus in cell culture. Science. 2005;309:623–626
  30. Zhong J, Gastaminza P, Cheng G, Kapadia S, Kato T, Burton DR, et al. Robust hepatitis C virus infection in vitro. Proc Natl Acad Sci U S A. 2005;102:9294–9299
  31. Liang Y, Zhou Y, Shen P. NF-kappaB and its regulation on the immune system. Cell Mol Immunol. 2004;1:343–350
  32. Mihm S, Herrmann E, Sarrazin U, Wagner Mv, Kronenberger B, Zeuzem S, et al. Association of serum interleukin-8 with virologic response to antiviral therapy in patients with chronic hepatitis C. J Hepatol. 2004;40:845–852
  33. Polyak SJ, Khabar KS, Rezeiq M, Gretch DR. Elevated levels of interleukin-8 in serum are associated with hepatitis C virus infection and resistance to interferon therapy. J Virol. 2001;75:6209–6211
  34. Falasca K, Ucciferri C, Dalessandro M, Zingariello P, Mancino P, Petrarca C, et al. Cytokine patterns correlate with liver damage in patients with chronic hepatitis B and C. Ann Clin Lab Sci. 2006;36:144–150
  35. Gonzalez-Amaro R, Garcia-Monzon C, Garcia-Buey L, Moreno-Otero R, Alonso JL, Yague E, et al. Induction of tumor necrosis factor alpha production by human hepatocytes in chronic viral hepatitis. J Exp Med. 1994;179:841–848
  36. Chuang E, Del Vecchio A, Smolinski S, Song XY, Sarisky RT. Biomedicines to reduce inflammation but not viral load in chronic HCV—what’s the sense?. Trends Biotechnol. 2004;22:517–523
  37. Mbow ML, Sarisky RT. What is disrupting IFN-alpha’s antiviral activity?. Trends Biotechnol. 2004;22:395–399
  38. Bradham CA, Plumpe J, Manns MP, Brenner DA, Trautwein C. Mechanisms of hepatic toxicity (I. TNF-induced liver injury). Am J Physiol. 1998;275:G387–G392
  39. Ando K, Hiroishi K, Kaneko T, Moriyama T, Muto Y, Kayagaki N, et al. Perforin, Fas/Fas ligand, and TNF-alpha pathways as specific and bystander killing mechanisms of hepatitis C virus-specific human CTL. J Immunol. 1997;158:5283–5291
  40. Henri S, Chevillard C, Mergani A, Paris P, Gaudart J, Camilla C, et al. Cytokine regulation of periportal fibrosis in humans infected with Schistosoma mansoni: IFN-gamma is associated with protection against fibrosis and TNF-alpha with aggravation of disease. J Immunol. 2002;169:929–936
  41. Polyak SJ. Resistance of hepatitis C virus to the host antiviral response. Future Virol. 2006;1:89–98
  42. Batts K, Ludwig J. Chronic hepatitis: an update on terminology and reporting. Am J Surg Pathol. 1995;19:1409–1417
  43. Koo BC, McPoland P, Wagoner JP, Kane OJ, Lohmann V, Polyak SJ. Relationships between hepatitis C virus replication and CXCL-8 production in vitro. J Virol. 2006;80:7885–7893
  44. Duan L, Carrier DJ, Clausen EC. Silymarin extraction from milk thistle using hot water. Appl Biochem Biotechnol. 2004;113–116:559–568
  45. Barreto JF, Wallace SN, Carrier DJ, Clausen EC. Extraction of nutraceuticals from milk thistle: I (Hot water extraction). Appl Biochem Biotechnol. 2003;105–108:881–889
  46. Wallace SN, Carrier DJ, Clausen E. Extraction of nutraceuticals from milk thistle: part II (Extraction with organic solvents). Appl Biochem Biotechnol. 2003;105–108:891–903
  47. Wallace SN, Carrier DJ, Clausen EC. Batch solvent extraction of flavanolignans from milk thistle (Silybum marianum L. Gaertner). Phytochem Anal. 2005;16:7–16
  48. Holtmann H, Winzen R, Holland P, Eickemeier S, Hoffmann E, Wallach D, et al. Induction of interleukin-8 synthesis integrates effects on transcription and mRNA degradation from at least 3 different cytokine- or stress-activated signal transduction pathways. Mol Cell Biol. 1999;19:6742–6753
  49. Mukaida N, Shiroo M, Matsushima K. Genomic structure of the human monocyte-derived neutrophil chemotactic factor IL-8. J Immunol. 1989;143:1366–1371
  50. Wagoner J, Austin M, Green J, Imaizumi T, Casola A, Brasier A, et al. Regulation of CXCL-8 (interleukin-8) induction by double-stranded RNA signaling pathways during hepatitis C virus infection. J Virol. 2007;81:309–318
  51. Plumlee CR, Lazaro CA, Fausto N, Polyak SJ. Effect of ethanol on innate antiviral pathways and HCV replication in human liver cells. Virol J. 2005;2:89
  52. Varghese L, Agarwal C, Tyagi A, Singh RP, Agarwal R. Silibinin efficacy against human hepatocellular carcinoma. Clin Cancer Res. 2005;11:8441–8448
  53. Mukaida N. Interleukin-8: an expanding universe beyond neutrophil chemotaxis and activation. Int J Hematol. 2000;72:391–398
  54. Sumpter R, Loo YM, Foy E, Li K, Yoneyama M, Fujita T, et al. Regulating intracellular antiviral defense and permissiveness to hepatitis C virus RNA replication through a cellular RNA helicase, RIG-I. J Virol. 2005;79:2689–2699
  55. Darnell JE, Kerr IM, Stark GR. Jak–STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science. 1994;264:1415–1421
  56. Hannay JA, Yu D. Silibinin: a thorny therapeutic for EGF-R expressing tumors?. Cancer Biol Ther. 2003;2:532–533
  57. Dhanalakshmi S, Singh RP, Agarwal C, Agarwal R. Silibinin inhibits constitutive and TNFalpha-induced activation of NF-kappaB and sensitizes human prostate carcinoma DU145 cells to TNFalpha-induced apoptosis. Oncogene. 2002;21:1759–1767
  58. Schwarz KB. Oxidative stress during viral infection: a review. Free Radic Biol Med. 1996;21:641–649
  59. Wen F, Abdalla MY, Aloman C, Xiang J, Ahmad IM, Walewski J, et al. Increased prooxidant production and enhanced susceptibility to glutathione depletion in HepG2 cells co-expressing HCV core protein and CYP2E1. J Med Virol. 2004;72:230–240
  60. Qadri I, Iwahashi M, Capasso JM, Hopken MW, Flores S, Schaack J, et al. Induced oxidative stress and activated expression of manganese superoxide dismutase during hepatitis C virus replication: role of JNK, p38 MAPK and AP-1. Biochem J. 2004;378:919–928
  61. Rigamonti C, Mottaran E, Reale E, Rolla R, Cipriani V, Capelli F, et al. Moderate alcohol consumption increases oxidative stress in patients with chronic hepatitis C. Hepatology. 2003;38:42–49
  62. Wong RH, Yeh CY, Hsueh YM, Wang JD, Lei YC, Cheng TJ. Association of hepatitis virus infection, alcohol consumption and plasma vitamin A levels with urinary 8-hydroxydeoxyguanosine in chemical workers. Mutat Res. 2003;535:181–186
  63. Koken T, Serteser M, Kahraman A, Gokce C. Oxidative stress markers in hepatitis C infected hemodialysis patients. J Nephrol. 2002;15:302–307
  64. Lai MMC. Hepatitis C virus proteins: direct link to hepatic oxidative stress, steatosis, carcinogenesis and more. Gastroenterology. 2002;122:568–571
  65. Okuda M, Li K, Beard MR, Showalter LA, Scholle F, Lemon SM, et al. Mitochondrial injury, oxidative stress, and antioxidant gene expression are induced by hepatitis C virus core protein. Gastroenterology. 2002;122:366–375
  66. Gong G, Waris G, Tanveer R, Siddiqui A. Human hepatitis C virus NS5A protein alters intracellular calcium levels, induces oxidative stress, and activates STAT-3 and NF-kappa B. Proc Natl Acad Sci U S A. 2001;98:9599–9604
  67. Bureau C, Bernad J, Chaouche N, Orfila C, Beraud M, Gonindard C, et al. Nonstructural 3 protein of hepatitis C virus triggers an oxidative burst in human monocytes via activation of NADPH oxidase. J Biol Chem. 2001;276:23077–23083
  68. Vendemiale G, Grattagliano I, Portincasa P, Serviddio G, Palasciamo G, Altomare E. Oxidative stress in symptom-free HCV carriers: relation with ALT flare-up. Eur J Clin Invest. 2001;31:54–63
  69. Larrea E, Beloqui O, Munoz-Navas MA, Civeira MP, Prieto J. Superoxide dismutase in patients with chronic hepatitis C virus infection. Free Radic Biol Med. 1998;24:1235–1241
  70. Mattson MP. Oxidative stress, perturbed calcium homeostasis, and immune dysfunction in Alzheimer’s disease. J Neurovirol. 2002;8:539–550
  71. Cantor EJ, Mancini EV, Seth R, Yao XH, Netticadan T. Oxidative stress and heart disease: cardiac dysfunction, nutrition, and gene therapy. Curr Hypertens Rep. 2003;5:215–220
  72. Wang XW, Hussain SP, Huo TI, Wu CG, Forgues M, Hofseth LJ, et al. Molecular pathogenesis of human hepatocellular carcinoma. Toxicology. 2002;181–182:43–47
  73. Olinski R, Gackowski D, Foksinski M, Rozalski R, Roszkowski K, Jaruga P. Oxidative DNA damage: assessment of the role in carcinogenesis, atherosclerosis, and acquired immunodeficiency syndrome. Free Radic Biol Med. 2002;33:192–200
  74. Kabe Y, Ando K, Hirao S, Yoshida M, Handa H. Redox regulation of NF-kappaB activation: distinct redox regulation between the cytoplasm and the nucleus. Antioxid Redox Signal. 2005;7:395–403
  75. Meiss R, Heinrich U, Robenek H, Themann H. Effect of silybin on hepatic cell membranes after damage by polycyclic aromatic hydrocarbons (PAH). Agents Actions. 1982;12:254–257
  76. Sharma Y, Agarwal C, Singh AK, Agarwal R. Inhibitory effect of silibinin on ligand binding to erbB1 and associated mitogenic signaling, growth, and DNA synthesis in advanced human prostate carcinoma cells. Mol Carcinog. 2001;30:224–236
  77. Wormald S, Hilton DJ. Inhibitors of cytokine signal transduction. J Biol Chem. 2004;279:821–824
  78. Lee J, Wu CC, Lee KJ, Chuang TH, Katakura K, Liu YT, et al. Activation of anti-hepatitis C virus responses via Toll-like receptor 7. Proc Natl Acad Sci U S A. 2006;103:1828–1833
  79. Grandvaux N, Gaboriau F, Harris J, tenOever BR, Lin R, Hiscott J. Regulation of arginase II by interferon regulatory factor 3 and the involvement of polyamines in the antiviral response. FEBS J. 2005;272:3120–3131
  80. Grandvaux N, Servant MJ, tenOever B, Sen GC, Balachandran S, Barber GN, et al. Transcriptional profiling of interferon regulatory factor 3 target genes: direct involvement in the regulation of interferon-stimulated genes. J Virol. 2002;76:5532–5539
  81. Platanias LC. The p38 mitogen-activated protein kinase pathway and its role in interferon signaling. Pharmacol Ther. 2003;98:129–142
  82. Davis-Searles PR, Nakanishi Y, Kim NC, Graf TN, Oberlies NH, Wani MC, et al. Milk thistle and prostate cancer: differential effects of pure flavonolignans from Silybum marianum on antiproliferative end points in human prostate carcinoma cells. Cancer Res. 2005;65:4448–4457
  83. Dvorak Z, Kosina P, Walterova D, Simanek V, Bachleda P, Ulrichova J. Primary cultures of human hepatocytes as a tool in cytotoxicity studies: cell protection against model toxins by flavonolignans obtained from Silybum marianum. Toxicol Lett. 2003;137:201–212
  84. Liu J, Manheimer E, Tsutani K, Gluud C. Medicinal herbs for hepatitis C virus infection: a Cochrane hepatobiliary systematic review of randomized trials. Am J Gastroenterol. 2003;98:538–544
  85. Melhem A, Stern M, Shibolet O, Israeli E, Ackerman Z, Pappo O, et al. Treatment of chronic hepatitis C virus infection via antioxidants: results of a phase I clinical trial. J Clin Gastroenterol. 2005;39:737–742
  86. Jacobs BP, Dennehy C, Ramirez G, Sapp J, Lawrence VA. Milk thistle for the treatment of liver disease: a systematic review and meta-analysis. Am J Med. 2002;113:506–515
  87. Strickland GT, Tanamly MD, Tadros F, Labeeb S, Makld H, Nessim D, et al. Two-year results of a randomised double-blinded trial evaluating silymarin for chronic hepatitis C. Dig Liver Dis. 2005;37:542–543
  88. Pietschmann T, Kaul A, Koutsoudakis G, Shavinskaya A, Kallis S, Steinmann E, et al. Construction and characterization of infectious intragenotypic and intergenotypic hepatitis C virus chimeras. Proc Natl Acad Sci U S A. 2006;103:7408–7413
  89. Yi M, Villanueva RA, Thomas DL, Wakita T, Lemon SM. Production of infectious genotype 1a hepatitis C virus (Hutchinson strain) in cultured human hepatoma cells. Proc Natl Acad Sci U S A. 2006;103:2310–2315
  90. Gordon A, Hobbs DA, Bowden DS, Bailey MJ, Mitchell J, Francis AJ, et al. Effects of Silybum marianum on serum hepatitis C virus RNA, alanine aminotransferase levels and well-being in patients with chronic hepatitis C. J Gastroenterol Hepatol. 2006;21:275–280
  91. Tanamly MD, Tadros F, Labeeb S, Makld H, Shehata M, Mikhail N, et al. Randomised double-blinded trial evaluating silymarin for chronic hepatitis C in an Egyptian village: study description and 12-month results. Dig Liver Dis. 2004;36:752–759

 The authors of this study have no conflicts of interest to disclose.

PII: S0016-5085(07)00395-2

doi: 10.1053/j.gastro.2007.02.038

Gastroenterology
Volume 132, Issue 5 , Pages 1925-1936 , May 2007

Article Tools

* Image Usage & Resolution